José Ramón González Juanatey-rekin lankidetzan egindako argitalpenak (78)

2023

  1. Cardiogenic shock code 2023. Expert document for a multidisciplinary organization that allows quality care

    Revista Espanola de Cardiologia, Vol. 76, Núm. 4, pp. 261-269

  2. Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial

    International Journal of Cardiology, Vol. 391

  3. Coronary Artery Disease and Prognosis of Heart Failure with Reduced Ejection Fraction

    Journal of Clinical Medicine, Vol. 12, Núm. 8

  4. Economic evaluation of restrictive vs. liberal transfusion strategy following acute myocardial infarction (REALITY): trial-based cost-effectiveness and cost-utility analyses

    European heart journal. Quality of care & clinical outcomes, Vol. 9, Núm. 2, pp. 194-202

  5. Survival after Invasive or Conservative Management of Stable Coronary Disease

    Circulation, Vol. 147, Núm. 1, pp. 8-19

  6. Trends in cardiovascular care in the National Health System in Spain. Data from the RECALCAR project 2011-2020

    Revista Espanola de Cardiologia, Vol. 76, Núm. 7, pp. 519-530

2022

  1. A cost-effectiveness analysis of patiromer for the treatment of hyperkalemia in chronic kidney disease patients with and without heart failure in Spain

    Journal of Medical Economics, Vol. 25, Núm. 1, pp. 640-649

  2. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

    European Heart Journal, Vol. 43, Núm. 11, pp. 1059-1103

  3. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    European Heart Journal, Vol. 43, Núm. 11, pp. 1033-1058

  4. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    Cardiovascular research, Vol. 118, Núm. 6, pp. 1385-1412

  5. One-Year Major Cardiovascular Events After Restrictive Versus Liberal Blood Transfusion Strategy in Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Trial

    Circulation

  6. Renal Function Impact in the Prognostic Value of Galectin-3 in Acute Heart Failure

    Frontiers in Cardiovascular Medicine, Vol. 9

2021

  1. A 3-Biomarker 2-Point-Based Risk Stratification Strategy in Acute Heart Failure

    Frontiers in Physiology, Vol. 12

  2. Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events among Patients with Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial

    JAMA - Journal of the American Medical Association, Vol. 325, Núm. 6, pp. 552-560

  3. Ischemic etiology and prognosis in men and women with acute heart failure

    Journal of Clinical Medicine, Vol. 10, Núm. 8

  4. Persistent pulmonary hypertension in corrected valvular heart disease: Hemodynamic insights and long-term survival

    Journal of the American Heart Association, Vol. 10, Núm. 2, pp. 1-21

  5. Prognostic impact of hyponatraemia and hypernatraemia at admission and discharge in heart failure patients with preserved, mid-range and reduced ejection fraction

    Internal Medicine Journal, Vol. 51, Núm. 6, pp. 930-938

2020

  1. Prevalence, clinical profile and prognostic implications of interatrial block in patients admitted for heart failure

    REC: CardioClinics, Vol. 55, Núm. 3, pp. 155-164

2019

  1. Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction

    Internal Medicine Journal, Vol. 49, Núm. 12, pp. 1505-1513

  2. Patient-Associated Predictors of 15- and 30-Day Readmission After Hospitalization for Acute Heart Failure

    Current Heart Failure Reports, Vol. 16, Núm. 6, pp. 304-314